NEWSPACE-CAPITAL
15.12.2022 08:31:42 CET | Business Wire | Press release
NewSpace Capital announces the first closing of its space-focused growth fund at €105M and a €15M lead investment in Cailabs’ series C investment round.
NewSpace Capital is a Luxembourg-based private equity fund dedicated to space-focused technology investments. The firm targets growth-equity opportunities in downstream applications and supply chain segments of the space market. NewSpace Capital has a global investment outlook with its main focus on Europe and the US. The closing was led by a cornerstone investment from Archean Capital Partners, a US fund dedicated to investing in emerging fund managers with specialized sector and operational experience. Other investors include corporates, financial institutions and family offices.
NewSpace Capital is also announcing a €15M investment in Cailabs, a French deep-tech company enabling revolutionary photonic solutions for industrial and communication applications. NewSpace Capital is the lead investor in Cailabs’ €26M series C financing round.
The fund’s other investments to date include ICEYE, which owns and operates the world’s largest constellation of synthetic aperture radar (SAR) satellites, and Kayrros, a climate-tech data analytics company that recently won the Financial Times’ prestigious 2022 Tech Champions Award.
Rob Lazaroff, Co-Portfolio Manager of Archean Capital said, “There are an increasing number of companies reaching the commercial stage in space, many of which are ready for growth stage capital. The NewSpace Capital team has an ideal mix of technical and commercial expertise to identify and select the best space companies, and help them achieve their growth plans.”
“We are very selective in backing new funds and we are willing to wait for the right combination of team, strategy and market opportunity. NewSpace Capital has an amazing network within the space ecosystem that makes them a preferred partner to companies like Cailabs. We are thrilled to support the team as they build NewSpace Capital into the next market leading private equity firm” said Chris Keller, Co-Portfolio Manager of Archean Capital.
“The space ecosystem becomes a backbone for economic and social change. We are a value investor in companies that enable this process with new technologies and capabilities. NewSpace Capital allows its LPs to tap into the growth segment of a €300-billion industry spanning Earth observation, communication and data analytics. We are excited to partner with Archean, whose team brings a wealth of knowledge and a unique partnership approach” said Bogdan Gogulan, CEO and Managing Partner of NewSpace Capital.
NewSpace Capital is a conduit to enable corporates and financial investors to achieve net-zero targets: “The space industry is critical to solving global ESG challenges. In addition to identifying, measuring, and mitigating the environmental impact of existent economic activity that can be done from space on a global scale, space infrastructure and space-enabled services also create a completely new way of operating for traditional industries, that allows the transition to a more efficient and net-zero economy,” said Felix von Schubert, Executive Chairman of NewSpace Capital.
About NewSpace Capital
NewSpace Capital is a global space-focused, growth-stage fund operated by a team that together has more than 150 years of investment, commercial and technical experience in the space and private equity industries. Based in Luxembourg, the fund provides growth capital to companies with a technological edge and leading market position in the supply chain and applications segments of the rapidly developing space ecosystem. To learn more visit www.newspace.capital
About Archean Capital Partners
Archean Capital Partners provides strategic anchor capital to newly-formed private equity firms. Archean was established in 2017 by Veritable, L.P. and Moelis Asset Management to provide initial limited partner capital and value-added support to highly qualified emerging managers. Archean is focused on opportunities in such specialties as buyout, growth, restructuring and turnaround. To learn more visit www.archeancapital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom